Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCDC vaccine + NeoDC vaccine
- Development stage
- Unknown
- Lead developer
- Sichuan University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
OCDC vaccine + NeoDC vaccine is a combination of two investigational therapeutic cancer vaccines developed by Sichuan University. Both components are dendritic cell (DC)-based vaccines designed to stimulate the immune system against tumor antigens. The "OCDC" and "NeoDC" vaccines utilize patient-derived dendritic cells pulsed with tumor antigens or personalized neoantigens to induce a targeted anti-tumor immune response. This approach aims to enhance the presentation of tumor-specific antigens to T cells, thereby promoting an effective cytotoxic response against cancer cells. The combination has been studied in various solid tumors including esophageal squamous cell carcinoma (locally advanced and unresectable), bladder cancer, melanoma, colorectal cancer, hepatocellular carcinoma, stomach cancer, and non-small cell lung cancer[1].
- Other names
- OCDC vaccineNeoDC vaccine
02
Targets
MHC I (MHC class I})
Beyond the preview
Go deeper on OCDC vaccine + NeoDC vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OCDC vaccine + NeoDC vaccine.